#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3 .
1-1	0-1	3	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=The statistical analysis of the collected data at each visit shows a very good trend for hydrogel containing trehalose and ceramides based ingredient at each visit :
3-1	15-18	The	abstract[3]	new[3]	_	_
3-2	19-30	statistical	abstract[3]	new[3]	_	_
3-3	31-39	analysis	abstract[3]	new[3]	_	_
3-4	40-42	of	abstract[3]	new[3]	_	_
3-5	43-46	the	abstract[3]|abstract[4]	new[3]|new[4]	_	_
3-6	47-56	collected	abstract[3]|abstract[4]	new[3]|new[4]	_	_
3-7	57-61	data	abstract[3]|abstract[4]	new[3]|new[4]	_	_
3-8	62-64	at	abstract[3]|abstract[4]	new[3]|new[4]	_	_
3-9	65-69	each	abstract[3]|abstract[4]|event[5]	new[3]|new[4]|new[5]	coref	3-25[11_5]
3-10	70-75	visit	abstract[3]|abstract[4]|event[5]	new[3]|new[4]|new[5]	_	_
3-11	76-81	shows	_	_	_	_
3-12	82-83	a	abstract[6]	new[6]	_	_
3-13	84-88	very	abstract[6]	new[6]	_	_
3-14	89-93	good	abstract[6]	new[6]	_	_
3-15	94-99	trend	abstract[6]	new[6]	_	_
3-16	100-103	for	abstract[6]	new[6]	_	_
3-17	104-112	hydrogel	abstract[6]|substance	new[6]|new	coref	5-22[26_0]
3-18	113-123	containing	_	_	_	_
3-19	124-133	trehalose	substance	new	coref	5-21
3-20	134-137	and	_	_	_	_
3-21	138-147	ceramides	substance	new	coref	5-19[22_0]
3-22	148-153	based	substance[10]	new[10]	coref	5-23[0_10]
3-23	154-164	ingredient	substance[10]	new[10]	_	_
3-24	165-167	at	substance[10]	new[10]	_	_
3-25	168-172	each	substance[10]|event[11]	new[10]|giv[11]	coref	8-25[48_11]
3-26	173-178	visit	substance[10]|event[11]	new[10]|giv[11]	_	_
3-27	179-180	:	_	_	_	_

#Text=Evaporimetry ( Transepidermal Water Loss ( TEWL ) )
4-1	181-193	Evaporimetry	substance	new	coref	5-1
4-2	194-195	(	_	_	_	_
4-3	196-210	Transepidermal	person[13]	new[13]	coref	43-1[307_13]
4-4	211-216	Water	person[13]	new[13]	_	_
4-5	217-221	Loss	person[13]	new[13]	_	_
4-6	222-223	(	person[13]	new[13]	_	_
4-7	224-228	TEWL	person[13]|abstract	new[13]|new	coref	12-8
4-8	229-230	)	person[13]	new[13]	_	_
4-9	231-232	)	_	_	_	_

#Text=Evaporimetry was used to detect any influence on the water barrier function of the skin following application of ceramides and trehalose based ingredient hydrogel and placebo hydrogel .
5-1	233-245	Evaporimetry	abstract	giv	coref	9-14
5-2	246-249	was	_	_	_	_
5-3	250-254	used	_	_	_	_
5-4	255-257	to	_	_	_	_
5-5	258-264	detect	_	_	_	_
5-6	265-268	any	abstract[16]	new[16]	_	_
5-7	269-278	influence	abstract[16]	new[16]	_	_
5-8	279-281	on	abstract[16]	new[16]	_	_
5-9	282-285	the	abstract[16]|abstract[19]	new[16]|new[19]	_	_
5-10	286-291	water	abstract[16]|substance|abstract[19]	new[16]|new|new[19]	coref	7-8
5-11	292-299	barrier	abstract[16]|object|abstract[19]	new[16]|new|new[19]	coref	7-17
5-12	300-308	function	abstract[16]|abstract[19]	new[16]|new[19]	_	_
5-13	309-311	of	abstract[16]|abstract[19]	new[16]|new[19]	_	_
5-14	312-315	the	abstract[16]|abstract[19]|object[20]	new[16]|new[19]|new[20]	coref	7-16[0_20]
5-15	316-320	skin	abstract[16]|abstract[19]|object[20]	new[16]|new[19]|new[20]	_	_
5-16	321-330	following	_	_	_	_
5-17	331-342	application	abstract[21]	new[21]	coref	11-3[0_21]
5-18	343-345	of	abstract[21]	new[21]	_	_
5-19	346-355	ceramides	abstract[21]|substance[22]	new[21]|giv[22]	coref	8-9[40_22]
5-20	356-359	and	abstract[21]|substance[22]	new[21]|giv[22]	_	_
5-21	360-369	trehalose	abstract[21]|substance[22]|substance	new[21]|giv[22]|giv	coref	8-11
5-22	370-375	based	abstract[21]|substance[22]|substance[26]	new[21]|giv[22]|giv[26]	coref	8-7[0_26]
5-23	376-386	ingredient	abstract[21]|substance[22]|substance|substance[26]	new[21]|giv[22]|giv|giv[26]	coref	8-13
5-24	387-395	hydrogel	abstract[21]|substance[22]|substance[26]	new[21]|giv[22]|giv[26]	_	_
5-25	396-399	and	abstract[21]|substance[22]|substance[26]	new[21]|giv[22]|giv[26]	_	_
5-26	400-407	placebo	abstract[21]|substance[22]|person|substance[26]	new[21]|giv[22]|new|giv[26]	coref	8-15
5-27	408-416	hydrogel	abstract[21]|substance[22]|substance[26]	new[21]|giv[22]|giv[26]	_	_
5-28	417-418	.	_	_	_	_

#Text=Corneometry ( Hydration )
6-1	419-430	Corneometry	substance	new	appos	6-3
6-2	431-432	(	_	_	_	_
6-3	433-442	Hydration	substance	giv	coref	7-20
6-4	443-444	)	_	_	_	_

#Text=In order to measure the amount of water present in the stratum corneum and the skin barrier condition , hydration has been evaluated through Corneometry .
7-1	445-447	In	_	_	_	_
7-2	448-453	order	_	_	_	_
7-3	454-456	to	_	_	_	_
7-4	457-464	measure	_	_	_	_
7-5	465-468	the	abstract[29]	new[29]	coref	22-19[131_29]
7-6	469-475	amount	abstract[29]	new[29]	_	_
7-7	476-478	of	abstract[29]	new[29]	_	_
7-8	479-484	water	abstract[29]|substance	new[29]|giv	coref	12-5
7-9	485-492	present	abstract[29]	new[29]	_	_
7-10	493-495	in	abstract[29]	new[29]	_	_
7-11	496-499	the	abstract[29]|place[32]	new[29]|new[32]	_	_
7-12	500-507	stratum	abstract[29]|abstract|place[32]	new[29]|new|new[32]	_	_
7-13	508-515	corneum	abstract[29]|place[32]	new[29]|new[32]	_	_
7-14	516-519	and	abstract[29]	new[29]	_	_
7-15	520-523	the	abstract[29]|abstract[35]	new[29]|new[35]	_	_
7-16	524-528	skin	abstract[29]|object|abstract[35]	new[29]|giv|new[35]	coref	9-30
7-17	529-536	barrier	abstract[29]|object|abstract[35]	new[29]|giv|new[35]	_	_
7-18	537-546	condition	abstract[29]|abstract[35]	new[29]|new[35]	_	_
7-19	547-548	,	_	_	_	_
7-20	549-558	hydration	abstract	giv	coref	7-25
7-21	559-562	has	_	_	_	_
7-22	563-567	been	_	_	_	_
7-23	568-577	evaluated	_	_	_	_
7-24	578-585	through	_	_	_	_
7-25	586-597	Corneometry	abstract	giv	coref	9-12
7-26	598-599	.	_	_	_	_

#Text=Moreover , the T-test applied to hydrogel containing ceramides and trehalose based ingredient and placebo formula gave a statistically significant difference between them at each visit , always showing better results for the hydrogel containing ceramides and trehalose based ingredient .
8-1	600-608	Moreover	_	_	_	_
8-2	609-610	,	_	_	_	_
8-3	611-614	the	abstract[38]	new[38]	_	_
8-4	615-621	T-test	abstract[38]	new[38]	_	_
8-5	622-629	applied	_	_	_	_
8-6	630-632	to	_	_	_	_
8-7	633-641	hydrogel	substance	giv	coref	8-33[50_0]
8-8	642-652	containing	_	_	_	_
8-9	653-662	ceramides	substance[40]	giv[40]	coref	8-36[51_40]
8-10	663-666	and	substance[40]	giv[40]	_	_
8-11	667-676	trehalose	substance[40]|substance	giv[40]|giv	coref	8-38
8-12	677-682	based	_	_	_	_
8-13	683-693	ingredient	substance|abstract[43]	giv|new[43]	ana|coref|ana|coref	8-23[47_43]|8-38[53_0]|8-23[47_43]|8-38[53_0]
8-14	694-697	and	abstract[43]	new[43]	_	_
8-15	698-705	placebo	abstract[43]|person|object[45]	new[43]|giv|new[45]	coref|coref|coref|coref	10-22|11-6[79_45]|10-22|11-6[79_45]
8-16	706-713	formula	abstract[43]|object[45]	new[43]|new[45]	_	_
8-17	714-718	gave	_	_	_	_
8-18	719-720	a	abstract[46]	new[46]	_	_
8-19	721-734	statistically	abstract[46]	new[46]	_	_
8-20	735-746	significant	abstract[46]	new[46]	_	_
8-21	747-757	difference	abstract[46]	new[46]	_	_
8-22	758-765	between	abstract[46]	new[46]	_	_
8-23	766-770	them	abstract[46]|abstract[47]	new[46]|giv[47]	coref	27-12[182_47]
8-24	771-773	at	abstract[46]|abstract[47]	new[46]|giv[47]	_	_
8-25	774-778	each	abstract[46]|abstract[47]|event[48]	new[46]|giv[47]|giv[48]	coref	10-13[71_48]
8-26	779-784	visit	abstract[46]|abstract[47]|event[48]	new[46]|giv[47]|giv[48]	_	_
8-27	785-786	,	_	_	_	_
8-28	787-793	always	_	_	_	_
8-29	794-801	showing	_	_	_	_
8-30	802-808	better	abstract[49]	new[49]	coref	10-1[67_49]
8-31	809-816	results	abstract[49]	new[49]	_	_
8-32	817-820	for	abstract[49]	new[49]	_	_
8-33	821-824	the	abstract[49]|substance[50]	new[49]|giv[50]	_	_
8-34	825-833	hydrogel	abstract[49]|substance[50]	new[49]|giv[50]	_	_
8-35	834-844	containing	_	_	_	_
8-36	845-854	ceramides	substance[51]	giv[51]	coref	9-27[0_51]
8-37	855-858	and	substance[51]	giv[51]	_	_
8-38	859-868	trehalose	substance[51]|substance|substance[53]	giv[51]|giv|giv[53]	coref|coref|coref|coref	9-25|10-10[70_53]|9-25|10-10[70_53]
8-39	869-874	based	substance[51]|substance[53]	giv[51]|giv[53]	_	_
8-40	875-885	ingredient	substance[51]|substance[53]	giv[51]|giv[53]	_	_
8-41	886-887	.	_	_	_	_

#Text=The double-blind , placebo-controlled study was performed to assess , by corneometry and evaporimetry , the barrier normalizing efficacy of a topical product containing trehalose and ceramides to alleviate skin dryness on limbs .
9-1	888-891	The	abstract[54]	new[54]	_	_
9-2	892-904	double-blind	abstract[54]	new[54]	_	_
9-3	905-906	,	_	_	_	_
9-4	907-925	placebo-controlled	abstract[55]	new[55]	coref	10-2[0_55]
9-5	926-931	study	abstract[55]	new[55]	_	_
9-6	932-935	was	_	_	_	_
9-7	936-945	performed	_	_	_	_
9-8	946-948	to	_	_	_	_
9-9	949-955	assess	_	_	_	_
9-10	956-957	,	_	_	_	_
9-11	958-960	by	_	_	_	_
9-12	961-972	corneometry	abstract	giv	coref	15-4
9-13	973-976	and	_	_	_	_
9-14	977-989	evaporimetry	object	giv	appos	9-16[58_0]
9-15	990-991	,	_	_	_	_
9-16	992-995	the	object[58]	giv[58]	coref	18-36[105_58]
9-17	996-1003	barrier	object[58]	giv[58]	_	_
9-18	1004-1015	normalizing	_	_	_	_
9-19	1016-1024	efficacy	abstract[59]	new[59]	_	_
9-20	1025-1027	of	abstract[59]	new[59]	_	_
9-21	1028-1029	a	abstract[59]|object[60]	new[59]|new[60]	coref	27-6[178_60]
9-22	1030-1037	topical	abstract[59]|object[60]	new[59]|new[60]	_	_
9-23	1038-1045	product	abstract[59]|object[60]	new[59]|new[60]	_	_
9-24	1046-1056	containing	_	_	_	_
9-25	1057-1066	trehalose	substance	giv	coref	11-10[80_0]
9-26	1067-1070	and	_	_	_	_
9-27	1071-1080	ceramides	substance	giv	coref	11-13
9-28	1081-1083	to	_	_	_	_
9-29	1084-1093	alleviate	_	_	_	_
9-30	1094-1098	skin	object|abstract[64]	giv|new[64]	coref|coref	18-32[104_0]|18-32[104_0]
9-31	1099-1106	dryness	abstract[64]	new[64]	_	_
9-32	1107-1109	on	_	_	_	_
9-33	1110-1115	limbs	object	new	_	_
9-34	1116-1117	.	_	_	_	_

#Text=The study results show a significant moisturizing effect of the ingredient at each visit , both versus baseline and versus the placebo control ( p < 0.01 ) .
10-1	1118-1121	The	abstract[67]	giv[67]	coref	18-1[96_67]
10-2	1122-1127	study	abstract|abstract[67]	giv|giv[67]	coref	27-3[177_0]
10-3	1128-1135	results	abstract[67]	giv[67]	_	_
10-4	1136-1140	show	_	_	_	_
10-5	1141-1142	a	abstract[69]	new[69]	coref	18-5[98_69]
10-6	1143-1154	significant	abstract[69]	new[69]	_	_
10-7	1155-1167	moisturizing	object|abstract[69]	new|new[69]	coref	18-7
10-8	1168-1174	effect	abstract[69]	new[69]	_	_
10-9	1175-1177	of	abstract[69]	new[69]	_	_
10-10	1178-1181	the	abstract[69]|substance[70]	new[69]|giv[70]	coref	11-14[82_70]
10-11	1182-1192	ingredient	abstract[69]|substance[70]	new[69]|giv[70]	_	_
10-12	1193-1195	at	abstract[69]|substance[70]	new[69]|giv[70]	_	_
10-13	1196-1200	each	abstract[69]|substance[70]|event[71]	new[69]|giv[70]|giv[71]	_	_
10-14	1201-1206	visit	abstract[69]|substance[70]|event[71]	new[69]|giv[70]|giv[71]	_	_
10-15	1207-1208	,	abstract[69]	new[69]	_	_
10-16	1209-1213	both	abstract[69]|abstract[72]	new[69]|new[72]	_	_
10-17	1214-1220	versus	abstract[69]|abstract[72]	new[69]|new[72]	_	_
10-18	1221-1229	baseline	abstract[69]|abstract[72]	new[69]|new[72]	_	_
10-19	1230-1233	and	_	_	_	_
10-20	1234-1240	versus	_	_	_	_
10-21	1241-1244	the	abstract[74]	new[74]	_	_
10-22	1245-1252	placebo	person|abstract[74]	giv|new[74]	coref	23-15[148_0]
10-23	1253-1260	control	abstract[74]	new[74]	_	_
10-24	1261-1262	(	_	_	_	_
10-25	1263-1264	p	quantity	new	coref	26-17
10-26	1265-1266	<	_	_	_	_
10-27	1267-1271	0.01	quantity	new	_	_
10-28	1272-1273	)	_	_	_	_
10-29	1274-1275	.	_	_	_	_

#Text=For the application site of topical cosmetic formula containing a trehalose and ceramides based ingredient :
11-1	1276-1279	For	_	_	_	_
11-2	1280-1283	the	place[78]	new[78]	coref	28-26[206_78]
11-3	1284-1295	application	abstract|place[78]	giv|new[78]	_	_
11-4	1296-1300	site	place[78]	new[78]	_	_
11-5	1301-1303	of	place[78]	new[78]	_	_
11-6	1304-1311	topical	place[78]|object[79]	new[78]|giv[79]	_	_
11-7	1312-1320	cosmetic	place[78]|object[79]	new[78]|giv[79]	_	_
11-8	1321-1328	formula	place[78]|object[79]	new[78]|giv[79]	_	_
11-9	1329-1339	containing	_	_	_	_
11-10	1340-1341	a	substance[80]	giv[80]	coref	21-16[0_80]
11-11	1342-1351	trehalose	substance[80]	giv[80]	_	_
11-12	1352-1355	and	_	_	_	_
11-13	1356-1365	ceramides	substance	giv	coref	21-18
11-14	1366-1371	based	substance[82]	giv[82]	coref	21-19[124_82]
11-15	1372-1382	ingredient	substance[82]	giv[82]	_	_
11-16	1383-1384	:	_	_	_	_

#Text=( 1 ) Transepidermal water loss ( TEWL ) value shows a reduction of −54 % after 4 weeks (
12-1	1385-1386	(	abstract[84]	new[84]	coref	22-35[136_84]
12-2	1387-1388	1	abstract[84]	new[84]	_	_
12-3	1389-1390	)	abstract[84]	new[84]	_	_
12-4	1391-1405	Transepidermal	abstract[84]	new[84]	_	_
12-5	1406-1411	water	substance|abstract[84]	giv|new[84]	coref	18-46
12-6	1412-1416	loss	abstract[84]	new[84]	_	_
12-7	1417-1418	(	_	_	_	_
12-8	1419-1423	TEWL	abstract	giv	coref	22-41
12-9	1424-1425	)	_	_	_	_
12-10	1426-1431	value	abstract	new	coref	26-14[173_0]
12-11	1432-1437	shows	_	_	_	_
12-12	1438-1439	a	abstract[87]	new[87]	_	_
12-13	1440-1449	reduction	abstract[87]	new[87]	_	_
12-14	1450-1452	of	abstract[87]	new[87]	_	_
12-15	1453-1456	−54	abstract[87]|quantity[88]	new[87]|new[88]	coref	15-9[93_88]
12-16	1457-1458	%	abstract[87]|quantity[88]	new[87]|new[88]	_	_
12-17	1459-1464	after	_	_	_	_
12-18	1465-1466	4	time[89]	new[89]	coref	15-12[94_89]
12-19	1467-1472	weeks	time[89]	new[89]	_	_
12-20	1473-1474	(	_	_	_	_

#Text=Figure 2
13-1	1475-1481	Figure	abstract[90]	new[90]	_	_
13-2	1482-1483	2	abstract[90]	new[90]	_	_

#Text=) .
14-1	1484-1485	)	_	_	_	_
14-2	1486-1487	.	_	_	_	_

#Text=( 2 ) Hydration shows an increase of 102 % after 4 weeks (
15-1	1488-1489	(	_	_	_	_
15-2	1490-1491	2	_	_	_	_
15-3	1492-1493	)	_	_	_	_
15-4	1494-1503	Hydration	abstract	giv	coref	34-16
15-5	1504-1509	shows	_	_	_	_
15-6	1510-1512	an	abstract[92]	new[92]	_	_
15-7	1513-1521	increase	abstract[92]	new[92]	_	_
15-8	1522-1524	of	abstract[92]	new[92]	_	_
15-9	1525-1528	102	abstract[92]|quantity[93]	new[92]|giv[93]	_	_
15-10	1529-1530	%	abstract[92]|quantity[93]	new[92]|giv[93]	_	_
15-11	1531-1536	after	_	_	_	_
15-12	1537-1538	4	time[94]	giv[94]	coref	27-56[196_94]
15-13	1539-1544	weeks	time[94]	giv[94]	_	_
15-14	1545-1546	(	_	_	_	_

#Text=Figure 3
16-1	1547-1553	Figure	abstract[95]	new[95]	_	_
16-2	1554-1555	3	abstract[95]	new[95]	_	_

#Text=) .
17-1	1556-1557	)	_	_	_	_
17-2	1558-1559	.	_	_	_	_

#Text=Such results point out the significant moisturizing effect after using the cosmetic under examination and go well with the rationale of the formulation , based on ingredients able to moisturize rapidly the skin and recover the cutaneous barrier to allow it to better hold the water present into its outer layers .
18-1	1560-1564	Such	abstract[96]	giv[96]	coref	25-2[154_96]
18-2	1565-1572	results	abstract[96]	giv[96]	_	_
18-3	1573-1578	point	_	_	_	_
18-4	1579-1582	out	_	_	_	_
18-5	1583-1586	the	abstract[98]	giv[98]	_	_
18-6	1587-1598	significant	abstract[98]	giv[98]	_	_
18-7	1599-1611	moisturizing	object|abstract[98]	giv|giv[98]	_	_
18-8	1612-1618	effect	abstract[98]	giv[98]	_	_
18-9	1619-1624	after	_	_	_	_
18-10	1625-1630	using	_	_	_	_
18-11	1631-1634	the	abstract[99]	new[99]	_	_
18-12	1635-1643	cosmetic	abstract[99]	new[99]	_	_
18-13	1644-1649	under	abstract[99]	new[99]	_	_
18-14	1650-1661	examination	abstract[99]|abstract	new[99]|new	_	_
18-15	1662-1665	and	_	_	_	_
18-16	1666-1668	go	_	_	_	_
18-17	1669-1673	well	_	_	_	_
18-18	1674-1678	with	_	_	_	_
18-19	1679-1682	the	abstract[101]	new[101]	ana	18-41[0_101]
18-20	1683-1692	rationale	abstract[101]	new[101]	_	_
18-21	1693-1695	of	abstract[101]	new[101]	_	_
18-22	1696-1699	the	abstract[101]|substance[102]	new[101]|new[102]	coref	20-6[113_102]
18-23	1700-1711	formulation	abstract[101]|substance[102]	new[101]|new[102]	_	_
18-24	1712-1713	,	_	_	_	_
18-25	1714-1719	based	_	_	_	_
18-26	1720-1722	on	_	_	_	_
18-27	1723-1734	ingredients	substance	new	_	_
18-28	1735-1739	able	_	_	_	_
18-29	1740-1742	to	_	_	_	_
18-30	1743-1753	moisturize	_	_	_	_
18-31	1754-1761	rapidly	_	_	_	_
18-32	1762-1765	the	object[104]	giv[104]	coref	20-11[115_104]
18-33	1766-1770	skin	object[104]	giv[104]	_	_
18-34	1771-1774	and	_	_	_	_
18-35	1775-1782	recover	_	_	_	_
18-36	1783-1786	the	object[105]	giv[105]	coref	22-32[134_105]
18-37	1787-1796	cutaneous	object[105]	giv[105]	_	_
18-38	1797-1804	barrier	object[105]	giv[105]	_	_
18-39	1805-1807	to	_	_	_	_
18-40	1808-1813	allow	_	_	_	_
18-41	1814-1816	it	abstract	giv	ana	18-49
18-42	1817-1819	to	_	_	_	_
18-43	1820-1826	better	_	_	_	_
18-44	1827-1831	hold	_	_	_	_
18-45	1832-1835	the	_	_	_	_
18-46	1836-1841	water	substance	giv	coref	22-38
18-47	1842-1849	present	_	_	_	_
18-48	1850-1854	into	_	_	_	_
18-49	1855-1858	its	abstract|object[109]	giv|new[109]	_	_
18-50	1859-1864	outer	object[109]	new[109]	_	_
18-51	1865-1871	layers	object[109]	new[109]	_	_
18-52	1872-1873	.	_	_	_	_

#Text=In vivo
19-1	1874-1876	In	_	_	_	_
19-2	1877-1881	vivo	abstract	new	_	_

#Text=evaluation of the efficacy of a formulation for atopic and very dry skin ( Xerosis ) was done .
20-1	1882-1892	evaluation	abstract[111]	new[111]	_	_
20-2	1893-1895	of	abstract[111]	new[111]	_	_
20-3	1896-1899	the	abstract[111]|abstract[112]	new[111]|new[112]	_	_
20-4	1900-1908	efficacy	abstract[111]|abstract[112]	new[111]|new[112]	_	_
20-5	1909-1911	of	abstract[111]|abstract[112]	new[111]|new[112]	_	_
20-6	1912-1913	a	abstract[111]|abstract[112]|substance[113]	new[111]|new[112]|giv[113]	coref	21-4[118_113]
20-7	1914-1925	formulation	abstract[111]|abstract[112]|substance[113]	new[111]|new[112]|giv[113]	_	_
20-8	1926-1929	for	abstract[111]|abstract[112]|substance[113]	new[111]|new[112]|giv[113]	_	_
20-9	1930-1936	atopic	abstract[111]|abstract[112]|substance[113]|substance	new[111]|new[112]|giv[113]|new	coref	21-8
20-10	1937-1940	and	abstract[111]|abstract[112]|substance[113]	new[111]|new[112]|giv[113]	_	_
20-11	1941-1945	very	abstract[111]|abstract[112]|substance[113]|object[115]	new[111]|new[112]|giv[113]|giv[115]	coref	27-44[193_115]
20-12	1946-1949	dry	abstract[111]|abstract[112]|substance[113]|object[115]	new[111]|new[112]|giv[113]|giv[115]	_	_
20-13	1950-1954	skin	abstract[111]|abstract[112]|substance[113]|object[115]	new[111]|new[112]|giv[113]|giv[115]	_	_
20-14	1955-1956	(	_	_	_	_
20-15	1957-1964	Xerosis	substance	new	_	_
20-16	1965-1966	)	_	_	_	_
20-17	1967-1970	was	_	_	_	_
20-18	1971-1975	done	_	_	_	_
20-19	1976-1977	.	_	_	_	_

#Text=An example of one topical formulation for atopic dermatitis ( Table 1 ) based on trehalose and ceramides based ingredient is reported below for illustrative and non-limiting purposes .
21-1	1978-1980	An	abstract[117]	new[117]	_	_
21-2	1981-1988	example	abstract[117]	new[117]	_	_
21-3	1989-1991	of	abstract[117]	new[117]	_	_
21-4	1992-1995	one	abstract[117]|substance[118]	new[117]|giv[118]	coref	23-4[144_118]
21-5	1996-2003	topical	abstract[117]|substance[118]	new[117]|giv[118]	_	_
21-6	2004-2015	formulation	abstract[117]|substance[118]	new[117]|giv[118]	_	_
21-7	2016-2019	for	abstract[117]|substance[118]	new[117]|giv[118]	_	_
21-8	2020-2026	atopic	abstract[117]|substance[118]|abstract|object[120]	new[117]|giv[118]|giv|new[120]	appos|coref|appos|coref	21-11[121_120]|27-42|21-11[121_120]|27-42
21-9	2027-2037	dermatitis	abstract[117]|substance[118]|object[120]	new[117]|giv[118]|new[120]	_	_
21-10	2038-2039	(	_	_	_	_
21-11	2040-2045	Table	object[121]	giv[121]	coref	22-23[132_121]
21-12	2046-2047	1	object[121]	giv[121]	_	_
21-13	2048-2049	)	_	_	_	_
21-14	2050-2055	based	_	_	_	_
21-15	2056-2058	on	_	_	_	_
21-16	2059-2068	trehalose	substance	giv	coref	23-9
21-17	2069-2072	and	_	_	_	_
21-18	2073-2082	ceramides	substance	giv	coref	23-11
21-19	2083-2088	based	substance[124]	giv[124]	coref	27-12[0_124]
21-20	2089-2099	ingredient	substance[124]	giv[124]	_	_
21-21	2100-2102	is	_	_	_	_
21-22	2103-2111	reported	_	_	_	_
21-23	2112-2117	below	_	_	_	_
21-24	2118-2121	for	_	_	_	_
21-25	2122-2134	illustrative	abstract[125]	new[125]	_	_
21-26	2135-2138	and	abstract[125]	new[125]	_	_
21-27	2139-2151	non-limiting	abstract[125]	new[125]	_	_
21-28	2152-2160	purposes	abstract[125]	new[125]	_	_
21-29	2161-2162	.	_	_	_	_

#Text=Purpose of the test : To provide active substances through a form that allows a prompt release and an effective amount in atopic dermatitis , characterized by a deteriorated functionality of the barrier , an increased transepidermal water loss ( TEWL ) and a significant xerosis , as well as in the case of pathologies associated with a local subcutaneous microcirculation disorder .
22-1	2163-2170	Purpose	abstract[126]	new[126]	_	_
22-2	2171-2173	of	abstract[126]	new[126]	_	_
22-3	2174-2177	the	abstract[126]|abstract[127]	new[126]|new[127]	coref	25-5[156_127]
22-4	2178-2182	test	abstract[126]|abstract[127]	new[126]|new[127]	_	_
22-5	2183-2184	:	_	_	_	_
22-6	2185-2187	To	_	_	_	_
22-7	2188-2195	provide	_	_	_	_
22-8	2196-2202	active	substance[128]	new[128]	_	_
22-9	2203-2213	substances	substance[128]	new[128]	_	_
22-10	2214-2221	through	_	_	_	_
22-11	2222-2223	a	object[129]	new[129]	_	_
22-12	2224-2228	form	object[129]	new[129]	_	_
22-13	2229-2233	that	_	_	_	_
22-14	2234-2240	allows	_	_	_	_
22-15	2241-2242	a	event[130]	new[130]	_	_
22-16	2243-2249	prompt	event[130]	new[130]	_	_
22-17	2250-2257	release	event[130]	new[130]	_	_
22-18	2258-2261	and	_	_	_	_
22-19	2262-2264	an	abstract[131]	giv[131]	_	_
22-20	2265-2274	effective	abstract[131]	giv[131]	_	_
22-21	2275-2281	amount	abstract[131]	giv[131]	_	_
22-22	2282-2284	in	abstract[131]	giv[131]	_	_
22-23	2285-2291	atopic	abstract[131]|object[132]	giv[131]|giv[132]	_	_
22-24	2292-2302	dermatitis	abstract[131]|object[132]	giv[131]|giv[132]	_	_
22-25	2303-2304	,	_	_	_	_
22-26	2305-2318	characterized	_	_	_	_
22-27	2319-2321	by	_	_	_	_
22-28	2322-2323	a	abstract[133]	new[133]	_	_
22-29	2324-2336	deteriorated	abstract[133]	new[133]	_	_
22-30	2337-2350	functionality	abstract[133]	new[133]	_	_
22-31	2351-2353	of	abstract[133]	new[133]	_	_
22-32	2354-2357	the	abstract[133]|object[134]	new[133]|giv[134]	_	_
22-33	2358-2365	barrier	abstract[133]|object[134]	new[133]|giv[134]	_	_
22-34	2366-2367	,	abstract[133]	new[133]	_	_
22-35	2368-2370	an	abstract[133]|abstract[136]	new[133]|giv[136]	coref	36-7[265_136]
22-36	2371-2380	increased	abstract[133]|abstract[136]	new[133]|giv[136]	_	_
22-37	2381-2395	transepidermal	abstract[133]|abstract[136]	new[133]|giv[136]	_	_
22-38	2396-2401	water	abstract[133]|substance|abstract[136]	new[133]|giv|giv[136]	coref	36-8
22-39	2402-2406	loss	abstract[133]|abstract[136]	new[133]|giv[136]	_	_
22-40	2407-2408	(	_	_	_	_
22-41	2409-2413	TEWL	abstract	giv	coref	34-18
22-42	2414-2415	)	_	_	_	_
22-43	2416-2419	and	_	_	_	_
22-44	2420-2421	a	abstract[138]	new[138]	coref	27-48[0_138]
22-45	2422-2433	significant	abstract[138]	new[138]	_	_
22-46	2434-2441	xerosis	abstract[138]	new[138]	_	_
22-47	2442-2443	,	abstract[138]	new[138]	_	_
22-48	2444-2446	as	abstract[138]	new[138]	_	_
22-49	2447-2451	well	abstract[138]	new[138]	_	_
22-50	2452-2454	as	abstract[138]	new[138]	_	_
22-51	2455-2457	in	abstract[138]	new[138]	_	_
22-52	2458-2461	the	abstract[138]|abstract[139]	new[138]|new[139]	_	_
22-53	2462-2466	case	abstract[138]|abstract[139]	new[138]|new[139]	_	_
22-54	2467-2469	of	abstract[138]|abstract[139]	new[138]|new[139]	_	_
22-55	2470-2481	pathologies	abstract[138]|abstract[139]|abstract	new[138]|new[139]|new	_	_
22-56	2482-2492	associated	_	_	_	_
22-57	2493-2497	with	_	_	_	_
22-58	2498-2499	a	abstract[142]	new[142]	_	_
22-59	2500-2505	local	abstract[142]	new[142]	_	_
22-60	2506-2518	subcutaneous	abstract[142]	new[142]	_	_
22-61	2519-2535	microcirculation	abstract|abstract[142]	new|new[142]	_	_
22-62	2536-2544	disorder	abstract[142]	new[142]	_	_
22-63	2545-2546	.	_	_	_	_

#Text=The efficacy of a topical cosmetic formulation containing trehalose and ceramides in comparison to a placebo has been evaluated .
23-1	2547-2550	The	abstract[143]	new[143]	_	_
23-2	2551-2559	efficacy	abstract[143]	new[143]	_	_
23-3	2560-2562	of	abstract[143]	new[143]	_	_
23-4	2563-2564	a	abstract[143]|substance[144]	new[143]|giv[144]	_	_
23-5	2565-2572	topical	abstract[143]|substance[144]	new[143]|giv[144]	_	_
23-6	2573-2581	cosmetic	abstract[143]|substance[144]	new[143]|giv[144]	_	_
23-7	2582-2593	formulation	abstract[143]|substance[144]	new[143]|giv[144]	_	_
23-8	2594-2604	containing	_	_	_	_
23-9	2605-2614	trehalose	substance	giv	coref	27-9
23-10	2615-2618	and	_	_	_	_
23-11	2619-2628	ceramides	substance	giv	coref	27-11
23-12	2629-2631	in	_	_	_	_
23-13	2632-2642	comparison	abstract[147]	new[147]	_	_
23-14	2643-2645	to	abstract[147]	new[147]	_	_
23-15	2646-2647	a	abstract[147]|person[148]	new[147]|giv[148]	coref	27-14[183_148]
23-16	2648-2655	placebo	abstract[147]|person[148]	new[147]|giv[148]	_	_
23-17	2656-2659	has	_	_	_	_
23-18	2660-2664	been	_	_	_	_
23-19	2665-2674	evaluated	_	_	_	_
23-20	2675-2676	.	_	_	_	_

#Text=Mean values , standard deviations , and variations were calculated for each set of values .
24-1	2677-2681	Mean	_	_	_	_
24-2	2682-2688	values	abstract	new	coref	24-15
24-3	2689-2690	,	_	_	_	_
24-4	2691-2699	standard	quantity[150]	new[150]	_	_
24-5	2700-2710	deviations	quantity[150]	new[150]	_	_
24-6	2711-2712	,	_	_	_	_
24-7	2713-2716	and	_	_	_	_
24-8	2717-2727	variations	abstract	new	coref	25-24[163_0]
24-9	2728-2732	were	_	_	_	_
24-10	2733-2743	calculated	_	_	_	_
24-11	2744-2747	for	_	_	_	_
24-12	2748-2752	each	abstract[152]	new[152]	_	_
24-13	2753-2756	set	abstract[152]	new[152]	_	_
24-14	2757-2759	of	abstract[152]	new[152]	_	_
24-15	2760-2766	values	abstract[152]|abstract	new[152]|giv	coref	38-6[276_0]
24-16	2767-2768	.	_	_	_	_

#Text=Following the results of normality test ( Kolmogorov – Smirnov test ) , the instrumental data ( T0 , T4 weeks ) and the variations ( T4 weeks-T0 ) were statistically compared by means of t -test for parametric and dependent data .
25-1	2769-2778	Following	_	_	_	_
25-2	2779-2782	the	abstract[154]	giv[154]	_	_
25-3	2783-2790	results	abstract[154]	giv[154]	_	_
25-4	2791-2793	of	abstract[154]	giv[154]	_	_
25-5	2794-2803	normality	abstract[154]|abstract|abstract[156]	giv[154]|new|giv[156]	appos|appos	25-10[159_156]|25-10[159_156]
25-6	2804-2808	test	abstract[154]|abstract[156]	giv[154]|giv[156]	_	_
25-7	2809-2810	(	_	_	_	_
25-8	2811-2821	Kolmogorov	person	new	_	_
25-9	2822-2823	–	_	_	_	_
25-10	2824-2831	Smirnov	person|abstract[159]	new|giv[159]	coref|coref	29-6[209_159]|29-6[209_159]
25-11	2832-2836	test	abstract[159]	giv[159]	_	_
25-12	2837-2838	)	_	_	_	_
25-13	2839-2840	,	_	_	_	_
25-14	2841-2844	the	abstract[160]	new[160]	appos	25-18[0_160]
25-15	2845-2857	instrumental	abstract[160]	new[160]	_	_
25-16	2858-2862	data	abstract[160]	new[160]	_	_
25-17	2863-2864	(	_	_	_	_
25-18	2865-2867	T0	abstract	giv	coref	25-39[168_0]
25-19	2868-2869	,	_	_	_	_
25-20	2870-2872	T4	time	new	coref	25-27
25-21	2873-2878	weeks	_	_	_	_
25-22	2879-2880	)	_	_	_	_
25-23	2881-2884	and	_	_	_	_
25-24	2885-2888	the	abstract[163]	giv[163]	_	_
25-25	2889-2899	variations	abstract[163]	giv[163]	_	_
25-26	2900-2901	(	_	_	_	_
25-27	2902-2904	T4	abstract|time[165]	giv|new[165]	_	_
25-28	2905-2913	weeks-T0	time[165]	new[165]	_	_
25-29	2914-2915	)	_	_	_	_
25-30	2916-2920	were	_	_	_	_
25-31	2921-2934	statistically	_	_	_	_
25-32	2935-2943	compared	_	_	_	_
25-33	2944-2946	by	_	_	_	_
25-34	2947-2952	means	_	_	_	_
25-35	2953-2955	of	_	_	_	_
25-36	2956-2957	t	abstract|abstract[167]	new|new[167]	_	_
25-37	2958-2963	-test	abstract[167]	new[167]	_	_
25-38	2964-2967	for	_	_	_	_
25-39	2968-2978	parametric	abstract[168]	giv[168]	coref	26-8[0_168]
25-40	2979-2982	and	abstract[168]	giv[168]	_	_
25-41	2983-2992	dependent	abstract[168]	giv[168]	_	_
25-42	2993-2997	data	abstract[168]	giv[168]	_	_
25-43	2998-2999	.	_	_	_	_

#Text=In all cases , the groups of data were considered statistically different for a probability value p < 0.05 .
26-1	3000-3002	In	_	_	_	_
26-2	3003-3006	all	object[169]	new[169]	_	_
26-3	3007-3012	cases	object[169]	new[169]	_	_
26-4	3013-3014	,	_	_	_	_
26-5	3015-3018	the	abstract[170]	new[170]	_	_
26-6	3019-3025	groups	abstract[170]	new[170]	_	_
26-7	3026-3028	of	abstract[170]	new[170]	_	_
26-8	3029-3033	data	abstract[170]|abstract	new[170]|giv	_	_
26-9	3034-3038	were	_	_	_	_
26-10	3039-3049	considered	_	_	_	_
26-11	3050-3063	statistically	_	_	_	_
26-12	3064-3073	different	_	_	_	_
26-13	3074-3077	for	_	_	_	_
26-14	3078-3079	a	abstract[173]	giv[173]	_	_
26-15	3080-3091	probability	abstract|abstract[173]	new|giv[173]	_	_
26-16	3092-3097	value	abstract[173]	giv[173]	_	_
26-17	3098-3099	p	quantity	giv	_	_
26-18	3100-3101	<	_	_	_	_
26-19	3102-3106	0.05	quantity	new	_	_
26-20	3107-3108	.	_	_	_	_

#Text=Protocol of double-blind study : the product containing trehalose and ceramides ingredient and the placebo was applied on the forearms by 20 volunteers of either sex ( 1 male and 19 females with an average age of 50 years ) with atopic and very dry skin ( xerosis ) , twice a day , for 4 weeks .
27-1	3109-3117	Protocol	abstract[176]	new[176]	_	_
27-2	3118-3120	of	abstract[176]	new[176]	_	_
27-3	3121-3133	double-blind	abstract[176]|abstract[177]	new[176]|giv[177]	coref	28-2[197_177]
27-4	3134-3139	study	abstract[176]|abstract[177]	new[176]|giv[177]	_	_
27-5	3140-3141	:	_	_	_	_
27-6	3142-3145	the	object[178]	giv[178]	coref	31-19[230_178]
27-7	3146-3153	product	object[178]	giv[178]	_	_
27-8	3154-3164	containing	_	_	_	_
27-9	3165-3174	trehalose	substance	giv	coref	30-20
27-10	3175-3178	and	_	_	_	_
27-11	3179-3188	ceramides	substance	giv	coref	30-22
27-12	3189-3199	ingredient	substance|abstract[182]	giv|giv[182]	coref|coref|coref|coref	30-23[222_0]|30-23[223_182]|30-23[222_0]|30-23[223_182]
27-13	3200-3203	and	abstract[182]	giv[182]	_	_
27-14	3204-3207	the	abstract[182]|person[183]	giv[182]|giv[183]	coref	30-26[0_183]
27-15	3208-3215	placebo	abstract[182]|person[183]	giv[182]|giv[183]	_	_
27-16	3216-3219	was	_	_	_	_
27-17	3220-3227	applied	_	_	_	_
27-18	3228-3230	on	_	_	_	_
27-19	3231-3234	the	object[184]	new[184]	coref	29-19[212_184]
27-20	3235-3243	forearms	object[184]	new[184]	_	_
27-21	3244-3246	by	_	_	_	_
27-22	3247-3249	20	person[185]	new[185]	coref	30-31[225_185]
27-23	3250-3260	volunteers	person[185]	new[185]	_	_
27-24	3261-3263	of	person[185]	new[185]	_	_
27-25	3264-3270	either	person[185]|event[186]	new[185]|new[186]	_	_
27-26	3271-3274	sex	person[185]|event[186]	new[185]|new[186]	_	_
27-27	3275-3276	(	_	_	_	_
27-28	3277-3278	1	person[187]|person[188]	new[187]|new[188]	ana|ana	28-10[0_188]|28-10[0_188]
27-29	3279-3283	male	person[187]|person[188]	new[187]|new[188]	_	_
27-30	3284-3287	and	person[188]	new[188]	_	_
27-31	3288-3290	19	person[188]|person[189]	new[188]|new[189]	_	_
27-32	3291-3298	females	person[188]|person[189]	new[188]|new[189]	_	_
27-33	3299-3303	with	person[188]|person[189]	new[188]|new[189]	_	_
27-34	3304-3306	an	person[188]|person[189]|abstract[190]	new[188]|new[189]|new[190]	_	_
27-35	3307-3314	average	person[188]|person[189]|abstract[190]	new[188]|new[189]|new[190]	_	_
27-36	3315-3318	age	person[188]|person[189]|abstract[190]	new[188]|new[189]|new[190]	_	_
27-37	3319-3321	of	person[188]|person[189]|abstract[190]	new[188]|new[189]|new[190]	_	_
27-38	3322-3324	50	person[188]|person[189]|abstract[190]|quantity[191]	new[188]|new[189]|new[190]|new[191]	_	_
27-39	3325-3330	years	person[188]|person[189]|abstract[190]|quantity[191]	new[188]|new[189]|new[190]|new[191]	_	_
27-40	3331-3332	)	_	_	_	_
27-41	3333-3337	with	_	_	_	_
27-42	3338-3344	atopic	substance	giv	_	_
27-43	3345-3348	and	_	_	_	_
27-44	3349-3353	very	object[193]	giv[193]	coref	28-15[0_193]
27-45	3354-3357	dry	object[193]	giv[193]	_	_
27-46	3358-3362	skin	object[193]	giv[193]	_	_
27-47	3363-3364	(	_	_	_	_
27-48	3365-3372	xerosis	abstract	giv	_	_
27-49	3373-3374	)	_	_	_	_
27-50	3375-3376	,	_	_	_	_
27-51	3377-3382	twice	time[195]	new[195]	_	_
27-52	3383-3384	a	time[195]	new[195]	_	_
27-53	3385-3388	day	time[195]	new[195]	_	_
27-54	3389-3390	,	time[195]	new[195]	_	_
27-55	3391-3394	for	time[195]	new[195]	_	_
27-56	3395-3396	4	time[195]|time[196]	new[195]|giv[196]	coref	36-31[271_196]
27-57	3397-3402	weeks	time[195]|time[196]	new[195]|giv[196]	_	_
27-58	3403-3404	.	_	_	_	_

#Text=During the study , subjects were instructed to wash their body using their current skin care regimen and to not apply the tested products on any other site than the prescribed ones .
28-1	3405-3411	During	_	_	_	_
28-2	3412-3415	the	abstract[197]	giv[197]	coref	32-21[0_197]
28-3	3416-3421	study	abstract[197]	giv[197]	_	_
28-4	3422-3423	,	_	_	_	_
28-5	3424-3432	subjects	abstract	new	coref	29-9[210_0]
28-6	3433-3437	were	_	_	_	_
28-7	3438-3448	instructed	_	_	_	_
28-8	3449-3451	to	_	_	_	_
28-9	3452-3456	wash	_	_	_	_
28-10	3457-3462	their	person|object[200]	giv|new[200]	ana|ana	28-13|28-13
28-11	3463-3467	body	object[200]	new[200]	_	_
28-12	3468-3473	using	_	_	_	_
28-13	3474-3479	their	person|abstract[204]	giv|new[204]	_	_
28-14	3480-3487	current	abstract[204]	new[204]	_	_
28-15	3488-3492	skin	object|abstract[204]	giv|new[204]	coref	36-4
28-16	3493-3497	care	abstract|abstract[204]	new|new[204]	_	_
28-17	3498-3505	regimen	abstract[204]	new[204]	_	_
28-18	3506-3509	and	_	_	_	_
28-19	3510-3512	to	_	_	_	_
28-20	3513-3516	not	_	_	_	_
28-21	3517-3522	apply	_	_	_	_
28-22	3523-3526	the	object[205]	new[205]	coref	29-16[211_205]
28-23	3527-3533	tested	object[205]	new[205]	_	_
28-24	3534-3542	products	object[205]	new[205]	_	_
28-25	3543-3545	on	object[205]	new[205]	_	_
28-26	3546-3549	any	object[205]|place[206]	new[205]|giv[206]	_	_
28-27	3550-3555	other	object[205]|place[206]	new[205]|giv[206]	_	_
28-28	3556-3560	site	object[205]|place[206]	new[205]|giv[206]	_	_
28-29	3561-3565	than	object[205]|place[206]	new[205]|giv[206]	_	_
28-30	3566-3569	the	object[205]|place[206]|object[207]	new[205]|giv[206]|new[207]	_	_
28-31	3570-3580	prescribed	object[205]|place[206]|object[207]	new[205]|giv[206]|new[207]	_	_
28-32	3581-3585	ones	object[205]|place[206]|object[207]	new[205]|giv[206]|new[207]	_	_
28-33	3586-3587	.	_	_	_	_

#Text=For the whole duration of the test , the subjects were not allowed to use different products on the forearms and instructed to avoid UV exposure .
29-1	3588-3591	For	_	_	_	_
29-2	3592-3595	the	time[208]	new[208]	_	_
29-3	3596-3601	whole	time[208]	new[208]	_	_
29-4	3602-3610	duration	time[208]	new[208]	_	_
29-5	3611-3613	of	time[208]	new[208]	_	_
29-6	3614-3617	the	time[208]|abstract[209]	new[208]|giv[209]	_	_
29-7	3618-3622	test	time[208]|abstract[209]	new[208]|giv[209]	_	_
29-8	3623-3624	,	_	_	_	_
29-9	3625-3628	the	abstract[210]	giv[210]	coref	33-6[241_210]
29-10	3629-3637	subjects	abstract[210]	giv[210]	_	_
29-11	3638-3642	were	_	_	_	_
29-12	3643-3646	not	_	_	_	_
29-13	3647-3654	allowed	_	_	_	_
29-14	3655-3657	to	_	_	_	_
29-15	3658-3661	use	_	_	_	_
29-16	3662-3671	different	object[211]	giv[211]	coref	33-1[240_211]
29-17	3672-3680	products	object[211]	giv[211]	_	_
29-18	3681-3683	on	object[211]	giv[211]	_	_
29-19	3684-3687	the	object[211]|object[212]	giv[211]|giv[212]	coref	36-24[269_212]
29-20	3688-3696	forearms	object[211]|object[212]	giv[211]|giv[212]	_	_
29-21	3697-3700	and	_	_	_	_
29-22	3701-3711	instructed	_	_	_	_
29-23	3712-3714	to	_	_	_	_
29-24	3715-3720	avoid	_	_	_	_
29-25	3721-3723	UV	abstract|abstract[214]	new|new[214]	_	_
29-26	3724-3732	exposure	abstract[214]	new[214]	_	_
29-27	3733-3734	.	_	_	_	_

#Text=Furthermore , the side of application ( left or right forearm ) of the two formulations ( cream containing trehalose and ceramides based ingredient and placebo ) were randomized among the volunteers .
30-1	3735-3746	Furthermore	_	_	_	_
30-2	3747-3748	,	_	_	_	_
30-3	3749-3752	the	abstract[215]	new[215]	_	_
30-4	3753-3757	side	abstract[215]	new[215]	_	_
30-5	3758-3760	of	abstract[215]	new[215]	_	_
30-6	3761-3772	application	abstract[215]|abstract[216]	new[215]|new[216]	_	_
30-7	3773-3774	(	abstract[215]|abstract[216]	new[215]|new[216]	_	_
30-8	3775-3779	left	abstract[215]|abstract[216]	new[215]|new[216]	_	_
30-9	3780-3782	or	abstract[215]|abstract[216]	new[215]|new[216]	_	_
30-10	3783-3788	right	abstract[215]|abstract[216]|object[217]	new[215]|new[216]|new[217]	_	_
30-11	3789-3796	forearm	abstract[215]|abstract[216]|object[217]	new[215]|new[216]|new[217]	_	_
30-12	3797-3798	)	abstract[215]|abstract[216]	new[215]|new[216]	_	_
30-13	3799-3801	of	abstract[215]|abstract[216]	new[215]|new[216]	_	_
30-14	3802-3805	the	abstract[215]|abstract[216]|substance[218]	new[215]|new[216]|new[218]	appos	30-18[0_218]
30-15	3806-3809	two	abstract[215]|abstract[216]|substance[218]	new[215]|new[216]|new[218]	_	_
30-16	3810-3822	formulations	abstract[215]|abstract[216]|substance[218]	new[215]|new[216]|new[218]	_	_
30-17	3823-3824	(	_	_	_	_
30-18	3825-3830	cream	substance	giv	coref	39-9[294_0]
30-19	3831-3841	containing	_	_	_	_
30-20	3842-3851	trehalose	substance	giv	coref	38-25
30-21	3852-3855	and	_	_	_	_
30-22	3856-3865	ceramides	substance	giv	coref	39-6[290_0]
30-23	3866-3871	based	substance[222]|abstract[223]	giv[222]|giv[223]	coref|coref|coref|coref	34-8[247_222]|34-8[248_223]|34-8[247_222]|34-8[248_223]
30-24	3872-3882	ingredient	substance[222]|abstract[223]	giv[222]|giv[223]	_	_
30-25	3883-3886	and	abstract[223]	giv[223]	_	_
30-26	3887-3894	placebo	abstract[223]|person	giv[223]|giv	coref	34-11[249_0]
30-27	3895-3896	)	_	_	_	_
30-28	3897-3901	were	_	_	_	_
30-29	3902-3912	randomized	_	_	_	_
30-30	3913-3918	among	_	_	_	_
30-31	3919-3922	the	person[225]	giv[225]	_	_
30-32	3923-3933	volunteers	person[225]	giv[225]	_	_
30-33	3934-3935	.	_	_	_	_

#Text=Each sample was labeled “ right ” or “ left ” , indicating the side of application of the product .
31-1	3936-3940	Each	object[226]	new[226]	_	_
31-2	3941-3947	sample	object[226]	new[226]	_	_
31-3	3948-3951	was	_	_	_	_
31-4	3952-3959	labeled	_	_	_	_
31-5	3960-3961	“	_	_	_	_
31-6	3962-3967	right	abstract	new	_	_
31-7	3968-3969	”	_	_	_	_
31-8	3970-3972	or	_	_	_	_
31-9	3973-3974	“	_	_	_	_
31-10	3975-3979	left	_	_	_	_
31-11	3980-3981	”	_	_	_	_
31-12	3982-3983	,	_	_	_	_
31-13	3984-3994	indicating	_	_	_	_
31-14	3995-3998	the	abstract[228]	new[228]	_	_
31-15	3999-4003	side	abstract[228]	new[228]	_	_
31-16	4004-4006	of	abstract[228]	new[228]	_	_
31-17	4007-4018	application	abstract[228]|abstract[229]	new[228]|new[229]	_	_
31-18	4019-4021	of	abstract[228]|abstract[229]	new[228]|new[229]	_	_
31-19	4022-4025	the	abstract[228]|abstract[229]|object[230]	new[228]|new[229]|giv[230]	coref	38-30[286_230]
31-20	4026-4033	product	abstract[228]|abstract[229]|object[230]	new[228]|new[229]|giv[230]	_	_
31-21	4034-4035	.	_	_	_	_

#Text=The assignment of subject number and subsequent placement on the randomization chart were made in order of appearance at the study center on the first day .
32-1	4036-4039	The	abstract[231]	new[231]	_	_
32-2	4040-4050	assignment	abstract[231]	new[231]	_	_
32-3	4051-4053	of	abstract[231]	new[231]	_	_
32-4	4054-4061	subject	abstract[231]|abstract[232]	new[231]|new[232]	_	_
32-5	4062-4068	number	abstract[231]|abstract[232]	new[231]|new[232]	_	_
32-6	4069-4072	and	abstract[231]	new[231]	_	_
32-7	4073-4083	subsequent	abstract[231]|abstract[233]	new[231]|new[233]	_	_
32-8	4084-4093	placement	abstract[231]|abstract[233]	new[231]|new[233]	_	_
32-9	4094-4096	on	abstract[231]|abstract[233]	new[231]|new[233]	_	_
32-10	4097-4100	the	abstract[231]|abstract[233]|object[235]	new[231]|new[233]|new[235]	_	_
32-11	4101-4114	randomization	abstract[231]|abstract[233]|abstract|object[235]	new[231]|new[233]|new|new[235]	_	_
32-12	4115-4120	chart	abstract[231]|abstract[233]|object[235]	new[231]|new[233]|new[235]	_	_
32-13	4121-4125	were	_	_	_	_
32-14	4126-4130	made	_	_	_	_
32-15	4131-4133	in	_	_	_	_
32-16	4134-4139	order	_	_	_	_
32-17	4140-4142	of	_	_	_	_
32-18	4143-4153	appearance	event	new	_	_
32-19	4154-4156	at	_	_	_	_
32-20	4157-4160	the	place[238]	new[238]	_	_
32-21	4161-4166	study	abstract|place[238]	giv|new[238]	_	_
32-22	4167-4173	center	place[238]	new[238]	_	_
32-23	4174-4176	on	place[238]	new[238]	_	_
32-24	4177-4180	the	place[238]|time[239]	new[238]|new[239]	_	_
32-25	4181-4186	first	place[238]|time[239]	new[238]|new[239]	_	_
32-26	4187-4190	day	place[238]|time[239]	new[238]|new[239]	_	_
32-27	4191-4192	.	_	_	_	_

#Text=The products were given to the subjects in anonymous containers which did not provide any information about the treatment .
33-1	4193-4196	The	object[240]	giv[240]	_	_
33-2	4197-4205	products	object[240]	giv[240]	_	_
33-3	4206-4210	were	_	_	_	_
33-4	4211-4216	given	_	_	_	_
33-5	4217-4219	to	_	_	_	_
33-6	4220-4223	the	abstract[241]	giv[241]	_	_
33-7	4224-4232	subjects	abstract[241]	giv[241]	_	_
33-8	4233-4235	in	abstract[241]	giv[241]	_	_
33-9	4236-4245	anonymous	abstract[241]|object[242]	giv[241]|new[242]	_	_
33-10	4246-4256	containers	abstract[241]|object[242]	giv[241]|new[242]	_	_
33-11	4257-4262	which	_	_	_	_
33-12	4263-4266	did	_	_	_	_
33-13	4267-4270	not	_	_	_	_
33-14	4271-4278	provide	_	_	_	_
33-15	4279-4282	any	abstract[243]	new[243]	_	_
33-16	4283-4294	information	abstract[243]	new[243]	_	_
33-17	4295-4300	about	abstract[243]	new[243]	_	_
33-18	4301-4304	the	abstract[243]|event[244]	new[243]|new[244]	ana	35-1[0_244]
33-19	4305-4314	treatment	abstract[243]|event[244]	new[243]|new[244]	_	_
33-20	4315-4316	.	_	_	_	_

#Text=The comparisons evidenced statistically significant differences between studied ingredient and placebo for both parameters ( hydration and TEWL ) .
34-1	4317-4320	The	abstract[245]	new[245]	_	_
34-2	4321-4332	comparisons	abstract[245]	new[245]	_	_
34-3	4333-4342	evidenced	_	_	_	_
34-4	4343-4356	statistically	abstract[246]	new[246]	_	_
34-5	4357-4368	significant	abstract[246]	new[246]	_	_
34-6	4369-4380	differences	abstract[246]	new[246]	_	_
34-7	4381-4388	between	abstract[246]	new[246]	_	_
34-8	4389-4396	studied	abstract[246]|substance[247]|abstract[248]	new[246]|giv[247]|giv[248]	coref|coref	38-27[0_247]|38-27[0_247]
34-9	4397-4407	ingredient	abstract[246]|substance[247]|abstract[248]	new[246]|giv[247]|giv[248]	_	_
34-10	4408-4411	and	abstract[246]|abstract[248]	new[246]|giv[248]	_	_
34-11	4412-4419	placebo	abstract[246]|abstract[248]|person[249]	new[246]|giv[248]|giv[249]	coref	35-20[0_249]
34-12	4420-4423	for	abstract[246]|abstract[248]|person[249]	new[246]|giv[248]|giv[249]	_	_
34-13	4424-4428	both	abstract[246]|abstract[248]|person[249]|abstract[250]	new[246]|giv[248]|giv[249]|new[250]	_	_
34-14	4429-4439	parameters	abstract[246]|abstract[248]|person[249]|abstract[250]	new[246]|giv[248]|giv[249]|new[250]	_	_
34-15	4440-4441	(	_	_	_	_
34-16	4442-4451	hydration	substance|abstract[252]	giv|new[252]	coref|coref|coref|coref	36-4[262_0]|36-4[263_252]|36-4[262_0]|36-4[263_252]
34-17	4452-4455	and	abstract[252]	new[252]	_	_
34-18	4456-4460	TEWL	abstract[252]|quantity	new[252]|giv	coref	36-11
34-19	4461-4462	)	_	_	_	_
34-20	4463-4464	.	_	_	_	_

#Text=This means that the improvements observed in the active area were statistically higher than the improvements observed in the placebo area .
35-1	4465-4469	This	event	giv	coref	36-34
35-2	4470-4475	means	_	_	_	_
35-3	4476-4480	that	_	_	_	_
35-4	4481-4484	the	abstract[255]	new[255]	_	_
35-5	4485-4497	improvements	abstract[255]	new[255]	_	_
35-6	4498-4506	observed	_	_	_	_
35-7	4507-4509	in	_	_	_	_
35-8	4510-4513	the	place[256]	new[256]	coref	35-19[259_256]
35-9	4514-4520	active	place[256]	new[256]	_	_
35-10	4521-4525	area	place[256]	new[256]	_	_
35-11	4526-4530	were	_	_	_	_
35-12	4531-4544	statistically	_	_	_	_
35-13	4545-4551	higher	_	_	_	_
35-14	4552-4556	than	_	_	_	_
35-15	4557-4560	the	abstract[257]	new[257]	_	_
35-16	4561-4573	improvements	abstract[257]	new[257]	_	_
35-17	4574-4582	observed	_	_	_	_
35-18	4583-4585	in	_	_	_	_
35-19	4586-4589	the	place[259]	giv[259]	coref	36-16[267_259]
35-20	4590-4597	placebo	person|place[259]	giv|giv[259]	coref	38-31
35-21	4598-4602	area	place[259]	giv[259]	_	_
35-22	4603-4604	.	_	_	_	_

#Text=Instrumental measurements of skin hydration and transepidermal water loss ( TEWL ) were performed on a selected area ( 9 cm2 ) of the forearms at the baseline and after 4 weeks of treatment .
36-1	4605-4617	Instrumental	abstract[260]	new[260]	_	_
36-2	4618-4630	measurements	abstract[260]	new[260]	_	_
36-3	4631-4633	of	abstract[260]	new[260]	_	_
36-4	4634-4638	skin	abstract[260]|object|substance[262]|abstract[263]	new[260]|giv|giv[262]|giv[263]	coref|coref|coref|coref|coref|coref	37-1[274_262]|38-11|37-1[274_262]|38-11|37-1[274_262]|38-11
36-5	4639-4648	hydration	abstract[260]|substance[262]|abstract[263]	new[260]|giv[262]|giv[263]	_	_
36-6	4649-4652	and	abstract[260]|abstract[263]	new[260]|giv[263]	_	_
36-7	4653-4667	transepidermal	abstract[260]|abstract[263]|abstract[265]	new[260]|giv[263]|giv[265]	_	_
36-8	4668-4673	water	abstract[260]|abstract[263]|substance|abstract[265]	new[260]|giv[263]|giv|giv[265]	_	_
36-9	4674-4678	loss	abstract[260]|abstract[263]|abstract[265]	new[260]|giv[263]|giv[265]	_	_
36-10	4679-4680	(	_	_	_	_
36-11	4681-4685	TEWL	abstract	giv	coref	43-5
36-12	4686-4687	)	_	_	_	_
36-13	4688-4692	were	_	_	_	_
36-14	4693-4702	performed	_	_	_	_
36-15	4703-4705	on	_	_	_	_
36-16	4706-4707	a	place[267]	giv[267]	_	_
36-17	4708-4716	selected	place[267]	giv[267]	_	_
36-18	4717-4721	area	place[267]	giv[267]	_	_
36-19	4722-4723	(	_	_	_	_
36-20	4724-4725	9	quantity[268]	new[268]	_	_
36-21	4726-4729	cm2	quantity[268]	new[268]	_	_
36-22	4730-4731	)	_	_	_	_
36-23	4732-4734	of	_	_	_	_
36-24	4735-4738	the	object[269]	giv[269]	_	_
36-25	4739-4747	forearms	object[269]	giv[269]	_	_
36-26	4748-4750	at	object[269]	giv[269]	_	_
36-27	4751-4754	the	object[269]|abstract[270]	giv[269]|new[270]	_	_
36-28	4755-4763	baseline	object[269]|abstract[270]	giv[269]|new[270]	_	_
36-29	4764-4767	and	_	_	_	_
36-30	4768-4773	after	_	_	_	_
36-31	4774-4775	4	time[271]	giv[271]	coref	39-18[297_271]
36-32	4776-4781	weeks	time[271]	giv[271]	_	_
36-33	4782-4784	of	time[271]	giv[271]	_	_
36-34	4785-4794	treatment	time[271]|event	giv[271]|giv	coref	39-21
36-35	4795-4796	.	_	_	_	_

#Text=Skin Hydration
37-1	4797-4801	Skin	person|abstract[274]	new|giv[274]	coref|coref	38-11[278_274]|38-11[278_274]
37-2	4802-4811	Hydration	abstract[274]	giv[274]	_	_

#Text=A statistically significant increase in the mean basal values of skin hydration was evidenced after 4 weeks of application of both the ceramides and trehalose based ingredient cream and the placebo product ( Table 2 ) .
38-1	4812-4813	A	abstract[275]	new[275]	_	_
38-2	4814-4827	statistically	abstract[275]	new[275]	_	_
38-3	4828-4839	significant	abstract[275]	new[275]	_	_
38-4	4840-4848	increase	abstract[275]	new[275]	_	_
38-5	4849-4851	in	abstract[275]	new[275]	_	_
38-6	4852-4855	the	abstract[275]|abstract[276]	new[275]|giv[276]	_	_
38-7	4856-4860	mean	abstract[275]|abstract[276]	new[275]|giv[276]	_	_
38-8	4861-4866	basal	abstract[275]|abstract[276]	new[275]|giv[276]	_	_
38-9	4867-4873	values	abstract[275]|abstract[276]	new[275]|giv[276]	_	_
38-10	4874-4876	of	abstract[275]|abstract[276]	new[275]|giv[276]	_	_
38-11	4877-4881	skin	abstract[275]|abstract[276]|object|substance[278]	new[275]|giv[276]|giv|giv[278]	coref|coref|coref|coref	42-13|42-13[305_278]|42-13|42-13[305_278]
38-12	4882-4891	hydration	abstract[275]|abstract[276]|substance[278]	new[275]|giv[276]|giv[278]	_	_
38-13	4892-4895	was	_	_	_	_
38-14	4896-4905	evidenced	_	_	_	_
38-15	4906-4911	after	_	_	_	_
38-16	4912-4913	4	time[279]	new[279]	_	_
38-17	4914-4919	weeks	time[279]	new[279]	_	_
38-18	4920-4922	of	time[279]	new[279]	_	_
38-19	4923-4934	application	time[279]|abstract[280]	new[279]|new[280]	_	_
38-20	4935-4937	of	time[279]|abstract[280]	new[279]|new[280]	_	_
38-21	4938-4942	both	time[279]|abstract[280]|substance[281]	new[279]|new[280]|new[281]	coref	39-6[0_281]
38-22	4943-4946	the	time[279]|abstract[280]|substance[281]	new[279]|new[280]|new[281]	_	_
38-23	4947-4956	ceramides	time[279]|abstract[280]|substance[281]	new[279]|new[280]|new[281]	_	_
38-24	4957-4960	and	time[279]|abstract[280]	new[279]|new[280]	_	_
38-25	4961-4970	trehalose	time[279]|abstract[280]|substance	new[279]|new[280]|giv	coref	39-8
38-26	4971-4976	based	time[279]|abstract[280]|substance[284]	new[279]|new[280]|new[284]	coref	39-9[293_284]
38-27	4977-4987	ingredient	time[279]|abstract[280]|substance|substance[284]	new[279]|new[280]|giv|new[284]	coref	39-10
38-28	4988-4993	cream	time[279]|abstract[280]|substance[284]	new[279]|new[280]|new[284]	_	_
38-29	4994-4997	and	time[279]|abstract[280]	new[279]|new[280]	_	_
38-30	4998-5001	the	time[279]|abstract[280]|object[286]	new[279]|new[280]|giv[286]	coref	39-13[296_286]
38-31	5002-5009	placebo	time[279]|abstract[280]|person|object[286]	new[279]|new[280]|giv|giv[286]	coref	39-13
38-32	5010-5017	product	time[279]|abstract[280]|object[286]	new[279]|new[280]|giv[286]	_	_
38-33	5018-5019	(	_	_	_	_
38-34	5020-5025	Table	abstract[287]	new[287]	_	_
38-35	5026-5027	2	abstract[287]	new[287]	_	_
38-36	5028-5029	)	_	_	_	_
38-37	5030-5031	.	_	_	_	_

#Text=A statistically significant difference between ceramides and trehalose based ingredient cream and placebo product was detected after 4 weeks of treatment (
39-1	5032-5033	A	abstract[288]	new[288]	_	_
39-2	5034-5047	statistically	abstract[288]	new[288]	_	_
39-3	5048-5059	significant	abstract[288]	new[288]	_	_
39-4	5060-5070	difference	abstract[288]	new[288]	_	_
39-5	5071-5078	between	abstract[288]	new[288]	_	_
39-6	5079-5088	ceramides	abstract[288]|substance|substance[290]	new[288]|giv|giv[290]	coref|coref	42-6|42-6
39-7	5089-5092	and	abstract[288]|substance[290]	new[288]|giv[290]	_	_
39-8	5093-5102	trehalose	abstract[288]|substance[290]|substance	new[288]|giv[290]|giv	coref	42-4
39-9	5103-5108	based	abstract[288]|substance[290]|substance[293]|substance[294]	new[288]|giv[290]|giv[293]|giv[294]	coref|coref	42-1[300_293]|42-1[300_293]
39-10	5109-5119	ingredient	abstract[288]|substance[290]|substance|substance[293]|substance[294]	new[288]|giv[290]|giv|giv[293]|giv[294]	coref	42-8
39-11	5120-5125	cream	abstract[288]|substance[290]|substance[293]|substance[294]	new[288]|giv[290]|giv[293]|giv[294]	_	_
39-12	5126-5129	and	abstract[288]|substance[290]|substance[294]	new[288]|giv[290]|giv[294]	_	_
39-13	5130-5137	placebo	abstract[288]|substance[290]|substance[294]|person|object[296]	new[288]|giv[290]|giv[294]|giv|giv[296]	coref|coref	42-18|42-18
39-14	5138-5145	product	abstract[288]|substance[290]|substance[294]|object[296]	new[288]|giv[290]|giv[294]|giv[296]	_	_
39-15	5146-5149	was	_	_	_	_
39-16	5150-5158	detected	_	_	_	_
39-17	5159-5164	after	_	_	_	_
39-18	5165-5166	4	time[297]	giv[297]	_	_
39-19	5167-5172	weeks	time[297]	giv[297]	_	_
39-20	5173-5175	of	time[297]	giv[297]	_	_
39-21	5176-5185	treatment	time[297]|event	giv[297]|giv	_	_
39-22	5186-5187	(	_	_	_	_

#Text=Figure 4
40-1	5188-5194	Figure	abstract[299]	new[299]	_	_
40-2	5195-5196	4	abstract[299]	new[299]	_	_

#Text=) .
41-1	5197-5198	)	_	_	_	_
41-2	5199-5200	.	_	_	_	_

#Text=The cream containing trehalose and ceramides based ingredient is able to improve skin hydration if compared to placebo .
42-1	5201-5204	The	substance[300]	giv[300]	_	_
42-2	5205-5210	cream	substance[300]	giv[300]	_	_
42-3	5211-5221	containing	_	_	_	_
42-4	5222-5231	trehalose	substance	giv	_	_
42-5	5232-5235	and	_	_	_	_
42-6	5236-5245	ceramides	substance	giv	_	_
42-7	5246-5251	based	_	_	_	_
42-8	5252-5262	ingredient	substance	giv	_	_
42-9	5263-5265	is	_	_	_	_
42-10	5266-5270	able	_	_	_	_
42-11	5271-5273	to	_	_	_	_
42-12	5274-5281	improve	_	_	_	_
42-13	5282-5286	skin	object|substance[305]	giv|giv[305]	_	_
42-14	5287-5296	hydration	substance[305]	giv[305]	_	_
42-15	5297-5299	if	_	_	_	_
42-16	5300-5308	compared	_	_	_	_
42-17	5309-5311	to	_	_	_	_
42-18	5312-5319	placebo	person	giv	_	_
42-19	5320-5321	.	_	_	_	_

#Text=Transepidermal Water Loss ( TEWL )
43-1	5322-5336	Transepidermal	person[307]	giv[307]	_	_
43-2	5337-5342	Water	person[307]	giv[307]	_	_
43-3	5343-5347	Loss	person[307]	giv[307]	_	_
43-4	5348-5349	(	_	_	_	_
43-5	5350-5354	TEWL	abstract	giv	_	_
43-6	5355-5356	)	_	_	_	_
